Future of Kala Pharma's dry eye drug uncertain after mixed results

(Reuters) - Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday.